Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment.
Publication/Presentation Date
1-1-2003
Abstract
Hematopoietic progenitor cell transplantation is often associated with severe mucosal toxicity. The need for parenteral analgesics and parenteral nutrition are evidence of the severity of the problem in individual patients. However, the increased risk for systemic infection related to bacteremia associated with the breakdown of mucosal barriers is a significant cause of morbidity and mortality as well. There is a multitude of grading scales, demonstrating the lack of consensus among clinicians in this area. Multiple agents have been used prophylactically and therapeutically to address mucositis. While efforts have been less successful in the past, the advent of newer agents including amifostine, keratinocyte growth factor, transforming growth factor beta and interleukin-11 provides hope that this toxicity will be significantly decreased in the near future.
Volume
31
Issue
1
First Page
1
Last Page
10
ISSN
0268-3369
Published In/Presented At
Filicko, J., Lazarus, H. M., & Flomenberg, N. (2003). Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone marrow transplantation, 31(1), 1–10. https://doi.org/10.1038/sj.bmt.1703776
Disciplines
Medicine and Health Sciences
PubMedID
12621500
Department(s)
Hematology-Medical Oncology Division
Document Type
Article